GENE ONLINE|News &
Opinion
Blog

Zolgensma
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
After FDA Lifts Hold, Novartis to Proceed with Clinical Trials for Expensive Rare Disease Therapy
2021-08-04
Novartis’ Expensive Gene Therapy for SMA Reasserts its Efficacy in Two Clinical Trials
2021-06-24
New and Improved Base-Editing Tool Helps Cure Blindness in Mice
2020-10-25
Genentech Enters Spinal Muscular Atrophy Market with Risdiplam’s FDA Approval
2020-08-11
Spotlight: New Gene Therapies on the Horizon for the Treatment of Neurogenetic Diseases
2020-08-03
Novartis Wins Five Simultaneous Drug Approvals in Japan
2020-07-06
Spotlight: Roche’s SMA Drug, Risdiplam Makes Strong Case for Regulatory Approval
2020-07-05
R&D
Biogen’s SMA Drug, Spinraza Continues to Show Benefits in Pre-Symptomatic Patients
2020-06-14
R&D
Weekly Cover: Eisai to Launch “NouKNOWTM” in Japan for Regular Self-assessment of Brain Health
2020-03-26
FDA Okays Expensive Gene Therapy for Infantile-Onset Spinal Muscular Atrophy
2019-05-29
LATEST
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top